Overview
CJC-1295 + Ipamorelin is a research-grade peptide compound that has attracted significant attention in the scientific community for its role in bioactive optimization. Gold-standard GH optimization blend. Sustained pulsatile growth hormone release without cortisol spike.
This compound belongs to the bioactive category of research peptides and has been the subject of numerous preclinical investigations. Its unique molecular properties make it a valuable tool for researchers exploring novel therapeutic pathways.
CJC-1295 (DAC) extends GHRH half-life to ~8 days via DAC technology. Ipamorelin selectively stimulates GH release via ghrelin receptor without elevating cortisol or prolactin. The growing body of published literature continues to expand our understanding of this compound's potential applications in laboratory settings.
Mechanism of Action
CJC-1295 (DAC) extends GHRH half-life to ~8 days via DAC technology. Ipamorelin selectively stimulates GH release via ghrelin receptor without elevating cortisol or prolactin.
The signaling pathways activated by CJC-1295 + Ipamorelin continue to be mapped through proteomic and transcriptomic analyses. Current research focuses on identifying the specific receptor subtypes and downstream effectors responsible for the observed biological responses. Understanding these molecular interactions is critical for advancing the compound from preclinical investigation toward potential translational applications.
Research Areas
- Growth hormone secretion pathway analysis
- Neurotrophic factor expression research
- Receptor binding kinetics
- Hormonal axis modulation
- Signal transduction research
Compound Specifications
| CAS Number | 863288-34-0 · 170851-70-4 |
| Purity | ≥99% HPLC-MS verified |
| Storage | −20 °C. ≥24 months lyophilised. |
| Category | Bioactive |
| Price | €49 |
| Format | 10mg (5+5) lyophilised |
Available Formats
- 5+5mg vial set
- 10+10mg vial set
Dissolution
Use our dilution calculator for precise concentration calculations.